This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bergmann, J. S.
Right arrow Articles by Woods, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bergmann, J. S.
Right arrow Articles by Woods, G. L.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, October 1998, p. 2940-2943, Vol. 36, No. 10
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Evaluation of the ESP Culture System II for Testing Susceptibilities of Mycobacterium tuberculosis Isolates to Four Primary Antituberculous Drugs

John S. Bergmann and Gail L. Woods*

Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555-0740.

Received 25 March 1998/Returned for modification 25 May 1998/Accepted 1 July 1998

The reliability of the ESP Culture System II (herein referred to as ESP II) for testing susceptibilities of Mycobacterium tuberculosis isolates to isoniazid, rifampin, ethambutol, and streptomycin was evaluated by comparing results to those of the method of proportion (MOP), which was considered the reference method, for 20 clinical isolates and 30 challenge strains provided by the Centers for Disease Control and Prevention (CDC). Clinical isolates also were tested with the BACTEC TB 460 system; these results agreed with those obtained by the MOP for all isolates and all drugs, except the high concentration of isoniazid, for which agreement was 95%. After resolution of discrepancies, levels of agreement between ESP II and MOP for the clinical isolates were 95 and 100%, respectively, for the low and high concentrations of isoniazid, 100% for rifampin and ethambutol, and 95% for streptomycin. For the 30 challenge isolates, ESP II results for both concentrations of isoniazid agreed with the expected results in all cases, whereas agreement was 93% for both rifampin and streptomycin and 90% for ethambutol. All discrepancies with the CDC isolates were due to failure of ESP II to correctly classify resistant strains. By testing isolates yielding discrepant ethambutol and streptomycin results with a lower concentration of both drugs in the ESP II system, agreement increased to 93% for ethambutol and 100% for streptomycin. For the clinical isolates, the times to an ESP II result of susceptible (means ± standard errors of the means) were 8.47 ± 0.12 days (range, 7 to 10 days) and 8.73 ± 0.29 days (range, 5 to 11 days) when the inoculum was prepared from a McFarland equivalent and from a seed bottle, respectively. The time to an ESP II result of resistant varied by drug and method of inoculum preparation, ranging from 5.50 ± 0.22 days for ethambutol with the inoculum prepared from a McFarland standard to 8.0 days for ethambutol with the inoculum prepared from a seed bottle. These data suggest that the ESP II system is a rapid and reliable method for testing susceptibilities of M. tuberculosis isolates to isoniazid and rifampin. Performance, however, may be suboptimal for ethambutol and streptomycin. Testing additional ethambutol-resistant and streptomycin-resistant strains with two concentrations of both drugs is necessary.

* Corresponding author. Mailing address: Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-0740. Phone: (409) 772-4851. Fax: (409) 772-5683. E-mail: gwoods{at}utmb.edu.

Journal of Clinical Microbiology, October 1998, p. 2940-2943, Vol. 36, No. 10
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Werngren, J., Klintz, L., Hoffner, S. E. (2006). Evaluation of a Novel Kit for Use with the BacT/ALERT 3D System for Drug Susceptibility Testing of Mycobacterium tuberculosis.. J. Clin. Microbiol. 44: 2130-2132 [Abstract] [Full Text]  
  • Piersimoni, C., Olivieri, A., Benacchio, L., Scarparo, C. (2006). Current Perspectives on Drug Susceptibility Testing of Mycobacterium tuberculosis Complex: the Automated Nonradiometric Systems. J. Clin. Microbiol. 44: 20-28 [Full Text]  
  • Takii, T., Hamasaki, S., Hirano, K., Abe, C., Onozaki, K. (2005). Simple Fibroblast-Based Assay To Test the Pyrazinamide Susceptibility of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49: 804-807 [Abstract] [Full Text]  
  • Perez-Guzman, C., Vargas, M. H., Quinonez, F., Bazavilvazo, N., Aguilar, A., the Instituto Nacional de Enfermedades Respiratori, (2005). A Cholesterol-Rich Diet Accelerates Bacteriologic Sterilization in Pulmonary Tuberculosis. Chest 127: 643-651 [Abstract] [Full Text]  
  • Bemer, P., Bodmer, T., Munzinger, J., Perrin, M., Vincent, V., Drugeon, H. (2004). Multicenter Evaluation of the MB/BACT System for Susceptibility Testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 42: 1030-1034 [Abstract] [Full Text]  
  • Park, W. G., Bishai, W. R., Chaisson, R. E., Dorman, S. E. (2002). Performance of the Microscopic Observation Drug Susceptibility Assay in Drug Susceptibility Testing for Mycobacterium tuberculosis. J. Clin. Microbiol. 40: 4750-4752 [Abstract] [Full Text]  
  • Bemer, P., Palicova, F., Rusch-Gerdes, S., Drugeon, H. B., Pfyffer, G. E. (2002). Multicenter Evaluation of Fully Automated BACTEC Mycobacteria Growth Indicator Tube 960 System for Susceptibility Testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 40: 150-154 [Abstract] [Full Text]  
  • Ruiz, P., Zerolo, F. J., Casal, M. J. (2000). Comparison of Susceptibility Testing of Mycobacterium tuberculosis Using the ESP Culture System II with That Using the BACTEC Method. J. Clin. Microbiol. 38: 4663-4664 [Abstract] [Full Text]  
  • Brunello, F., Fontana, R. (2000). Reliability of the MB/BacT System for Testing Susceptibility of Mycobacterium tuberculosis Complex Isolates to Antituberculous Drugs. J. Clin. Microbiol. 38: 872-873 [Abstract] [Full Text]  
  • Eltringham, I. J., Wilson, S. M., Drobniewski, F. A. (1999). Evaluation of a Bacteriophage-Based Assay (Phage Amplified Biologically Assay) as a Rapid Screen for Resistance to Isoniazid, Ethambutol, Streptomycin, Pyrazinamide, and Ciprofloxacin among Clinical Isolates of Mycobacterium tuberculosis. J. Clin. Microbiol. 37: 3528-3532 [Abstract] [Full Text]  
  • Pfyffer, G. E., Bonato, D. A., Ebrahimzadeh, A., Gross, W., Hotaling, J., Kornblum, J., Laszlo, A., Roberts, G., Salfinger, M., Wittwer, F., Siddiqi, S. (1999). Multicenter Laboratory Validation of Susceptibility Testing of Mycobacterium tuberculosis against Classical Second-Line and Newer Antimicrobial Drugs by Using the Radiometric BACTEC 460 Technique and the Proportion Method with Solid Media. J. Clin. Microbiol. 37: 3179-3186 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»